Program builds on Lumen’s leading position in the development
of complex biologic drug cocktails
Seattle, WA, December 23, 2022 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wound.
The objective of this research program is unique in that its goal is to prevent infections rather than treat them after they have already taken hold. This preventative approach will allow Lumen to develop an inexpensive, biologic drug cocktail against the most frequent, multi-drug resistant infecting pathogens. The therapeutic product would be administered and be designed to mitigate risks of antibiotic-resistant infections in resource constrained settings such as battlefield medicine and trauma care.
Preclinical in vivo studies demonstrate Lumen’s therapeutic approach could be effective in preventing and treating infections caused by antibiotic resistant bacterial pathogens.
“This therapeutic treatment offers the potential for an inexpensive and scalable solution to the growing problem of antimicrobial resistance,” said Nhi Khuong, Lumen’s VP, Preclinical and lead scientist on the project. “We appreciate this support from MTEC and look forward to the advancement of this promising treatment application.”
The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. The Lumen award was funded under MTEC solicitation and is funded by the Naval Medical Research Center. For more information, visit: www.mtec-sc.org.
Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for several prevalent, worldwide diseases—many of which currently lack effective treatments. The company’s unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches. Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, cardiometabolic disease, inflammatory bowel disease, norovirus, and traveler's diarrhea.